Tessier-Lavigne Marc's Form 4/A amendment
AmendedDenali Therapeutics Inc. (DNLI) · filed Jun 28, 2022
- Accession no.
- 0001714899-22-000101
- Filed
- Jun 28, 2022
- Trade date
- Mar 23, 2022
- Filing delay
- 97 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Mar 25, 2022
This filing lists 2 non-derivative transactions. Open-market sales total $676.6K. It was filed 97 days after the trade.
This amendment replaces 0001714899-22-000061 (filed Mar 25, 2022).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tessier-Lavigne MarcCIK 0001437435 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
For this amended Form 4 filing the only change is to add the signature.
- F2
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $32.76 to $33.75 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
Includes 2,074 restricted stock units.
- F4
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $33.76 to $34.69 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F5
The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee.
- F6
The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee.
- F7
The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee.